Raymond James & Associates Sells 221 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

Raymond James & Associates trimmed its position in Inspire Medical Systems, Inc. (NYSE:INSP – Get Rating) by 1.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,690 shares of the company’s stock after selling 221 shares during the quarter. Raymond James & Associates owned 0.05% of Inspire Medical Systems worth $3,700,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust acquired a new stake in Inspire Medical Systems in the first quarter valued at approximately $37,000. Arcadia Investment Management Corp MI acquired a new position in shares of Inspire Medical Systems during the fourth quarter worth $47,000. Harvest Fund Management Co. Ltd lifted its holdings in shares of Inspire Medical Systems by 323.4% during the fourth quarter. Harvest Fund Management Co. Ltd now owns 271 shares of the company’s stock worth $68,000 after purchasing an additional 207 shares during the period. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Inspire Medical Systems during the fourth quarter worth $83,000. Finally, Cowa LLC acquired a new position in shares of Inspire Medical Systems during the third quarter worth $89,000. Institutional investors and hedge funds own 97.04% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on INSP shares. KeyCorp lifted their price target on shares of Inspire Medical Systems from $303.00 to $321.00 in a report on Wednesday, May 3rd. UBS Group lifted their price target on shares of Inspire Medical Systems from $300.00 to $304.00 in a report on Wednesday, May 3rd. Truist Financial lifted their price target on shares of Inspire Medical Systems from $335.00 to $360.00 in a report on Thursday, May 18th. Lake Street Capital lifted their price target on shares of Inspire Medical Systems from $250.00 to $305.00 in a report on Wednesday, February 8th. Finally, 92 Resources reissued a “maintains” rating on shares of Inspire Medical Systems in a research note on Wednesday, May 3rd. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $312.56.

Insider Buying and Selling at Inspire Medical Systems

In other Inspire Medical Systems news, VP Steven Jandrich sold 1,727 shares of Inspire Medical Systems stock in a transaction on Monday, May 8th. The shares were sold at an average price of $280.12, for a total value of $483,767.24. Following the completion of the sale, the vice president now directly owns 4,371 shares of the company’s stock, valued at $1,224,404.52. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Jerry C. Griffin sold 529 shares of the stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $293.91, for a total transaction of $155,478.39. Following the completion of the transaction, the director now directly owns 3,671 shares of the company’s stock, valued at approximately $1,078,943.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Steven Jandrich sold 1,727 shares of the stock in a transaction that occurred on Monday, May 8th. The shares were sold at an average price of $280.12, for a total transaction of $483,767.24. Following the transaction, the vice president now directly owns 4,371 shares of the company’s stock, valued at $1,224,404.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 15,310 shares of company stock valued at $4,280,627. Corporate insiders own 4.50% of the company’s stock.

Inspire Medical Systems Trading Down 1.1 %

INSP opened at $296.53 on Friday. Inspire Medical Systems, Inc. has a 1-year low of $157.04 and a 1-year high of $314.36. The company has a market cap of $8.60 billion, a P/E ratio of -190.08 and a beta of 1.44. The company has a fifty day moving average price of $264.26 and a two-hundred day moving average price of $252.56.

Inspire Medical Systems (NYSE:INSP – Get Rating) last posted its quarterly earnings results on Tuesday, May 2nd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.17. Inspire Medical Systems had a negative net margin of 9.35% and a negative return on equity of 10.27%. The firm had revenue of $127.90 million during the quarter, compared to the consensus estimate of $120.06 million. During the same period in the previous year, the firm posted ($0.61) earnings per share. The business’s revenue was up 84.3% compared to the same quarter last year. On average, research analysts forecast that Inspire Medical Systems, Inc. will post -1.18 EPS for the current fiscal year.

Inspire Medical Systems Profile

(Get Rating)

Inspire Medical Systems, Inc engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead.